Core Insights - IQVIA Holdings Analytics Inc. reported strong third-quarter 2025 results, with earnings and revenues exceeding the Zacks Consensus Estimate [1][9] - Adjusted earnings were $3 per share, a 5.6% increase year-over-year, while total revenues reached $4.1 billion, reflecting a 5.2% growth from the previous year [1][9] Financial Performance - The Research and Development segment generated revenues of $2.3 billion, up 4.5% year-over-year, surpassing the estimate of $2.2 billion [3] - Technology and Analytics segment revenues were $1.6 billion, growing 5% year-over-year, but fell short of the projected $1.7 billion [3] - Contract Sales and Medical Solutions revenues increased 16.1% year-over-year to $209 million, exceeding the estimate of $181.7 million [4] - Adjusted EBITDA for the quarter was $949 million, a 1.1% rise from the previous year, surpassing the anticipated $945.3 million [4] Cash Flow and Debt - The company ended the quarter with cash and cash equivalents of $1.8 billion, down from $2 billion in the previous quarter [5] - Long-term debt decreased to $15 billion from $15.4 billion at the end of the second quarter [5] - Net cash generated from operating activities was $908 million, with capital expenditures of $136 million, resulting in a free cash flow of $772 million for the quarter [5] 2025 Guidance - IQVIA updated its revenue guidance for 2025 to a range of $16.15-$16.25 billion, with the midpoint exceeding the Zacks Consensus Estimate of $16.16 billion [6] - The earnings per share outlook was revised to $11.85-$11.95, with the midpoint also above the consensus estimate of $11.86 [6] - Adjusted EBITDA guidance was updated to $3.775-$3.800 billion, reflecting a slight increase from the previous quarter's view [7]

Core Insights - IQVIA Holdings Analytics Inc. reported strong second-quarter 2025 results, with adjusted earnings of $2.81 per share, exceeding estimates by 1.8% and reflecting a 6.4% year-over-year increase. Total revenues reached $4 billion, surpassing consensus estimates by 1.5% and growing 5.3% from the previous year [1][9]. Financial Performance - The Research and Development segment generated revenues of $2.2 billion, a 2.5% increase year-over-year, while the Technology and Analytics segment saw revenues of $1.6 billion, up 8.9% from the prior year [3][9]. - Contract Sales and Medical Solutions revenues rose 9.3% year-over-year to $188 million, exceeding estimates of $181.9 million. Adjusted EBITDA for the quarter was $910 million, a 2.6% increase from the previous year, beating projections of $899.4 million [4][9]. Cash Flow and Debt - The company ended the quarter with cash and cash equivalents of $2 billion, up from $1.7 billion in the previous quarter. Long-term debt increased to $15.5 billion from $13.1 billion [5]. - Net cash generated from operating activities was $443 million, with capital expenditures of $151 million, resulting in a free cash flow of $292 million for the quarter [5]. 2025 Guidance - IQVIA updated its revenue guidance for 2025 to a range of $16.10-$16.30 billion, higher than the previous estimate and above the Zacks Consensus Estimate of $16.06 billion. However, adjusted EBITDA guidance was lowered to $3.75-$3.825 billion from the previous range [6][7]. - The adjusted EPS guidance was also updated to $11.75-$12.05, with the midpoint of $11.90 exceeding the Zacks Consensus Estimate of $11.84 [7].

Core Viewpoint - IQVIA Holdings Analytics Inc. reported strong first-quarter 2025 results, with earnings and revenues exceeding expectations, indicating positive growth trends in its business segments [1][7]. Financial Performance - Adjusted earnings were $2.70 per share, surpassing the Zacks Consensus Estimate by 2.7% and increasing 6.3% year-over-year [1]. - Total revenues reached $3.8 billion, exceeding the consensus estimate by 1.6% and growing 2.5% from the previous year [1]. - Adjusted EBITDA for the quarter was $883 million, a 2.4% increase from the year-ago quarter, but slightly below projections [5]. Segment Performance - The Research and Development segment generated revenues of $2.1 billion, showing a marginal increase year-over-year and meeting estimates [3]. - Revenues from the Technology and Analytics segment were $1.5 billion, growing 6.4% year-over-year and meeting estimates [4]. - Contract Sales and Medical Solutions revenues decreased 4.2% year-over-year to $181 million, missing estimates [4]. Cash Flow and Debt - Net cash generated from operating activities was $586 million, with capital expenditures of $142 million, resulting in a free cash flow of $426 million [6]. - The company ended the quarter with cash and cash equivalents of $1.7 billion, unchanged from the previous quarter, while long-term debt increased to $13.1 billion [5]. 2025 Guidance - For 2025, IQVIA raised its revenue guidance to $16.00-$16.40 billion, higher than the previous estimate and the Zacks Consensus Estimate of $15.86 billion [7]. - The company expects adjusted EPS in the range of $11.70-$12.10, with the midpoint exceeding the Zacks Consensus Estimate of $11.84 [7]. - Adjusted EBITDA guidance for 2025 is set at $3.76-$3.88 billion [7].